mercredi 29 novembre 2017

Onco Actu du 29 novembre 2017

3. Prévention

Increased Oral Pathogens and Decreased Bacterial Diversity Predict Precancerous Lesions of Stomach Cancer [NYU]

3.1 Prévention - Tabac

An Important Moment in Tobacco Control [NCI]

4. Dépistage, diagnostic et pronostic

The microscope makers [Nature]

4.1 Dép., diag. & prono. - Prostate

Median Technologies inks a collaboration agreement with Memorial Sloan Kettering Cancer Center for a study dealing with prostate cancer [Median]

4.2 Dép., diag. & prono. - Génome

Illumina Opens First Commercial and Customer Training Center in France [Illumina]

4.9 Dép., diag. & prono. - Sein

Abbreviated Breast MRI May Be Additional Screening Option for Dense Breasts [Penn Medicine]

5. Traitements

Our milestones: Nudging breast cancer radiotherapy in the right direction [Cancer Research UK]

5.12.2 Immunothérapies - CAR-T

Molecular profiling of melanoma tumours explains differences in survival after T cell therapy [Lund University]

5.12.4 Immunothérapies - Essais

Pfizer, Merck KGaA's Bavencio flops in 'high-risk' stomach cancer trial [FiercePharma]

Chemo Tops Pfizer, Merck KGaA Drug in Big Stomach Cancer Test [Xconomy]

Brace for More Cancer-Drug Trial Failures [Bloomberg]

Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study [EndPoints]

5.12.5 Immunothérapies - Pharma

European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma [BMS]

5.2 Pharma

Merck In London – A Hub, or Not? [In the Pipeline]

5.2.1 Pharma - Partenariats

AZ teams up with G1 on lung cancer combo [PharmaTimes]

5.2.3 Pharma - économie

A Grim Future? Here Are the Numbers. [In the Pipeline]

Pharma’s broken business model: An industry on the brink of terminal decline [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

Vemurafenib Becomes First FDA-approved Treatment for a Rare Type of Blood Cancer [Cancer Research Catalyst]

5.8 ASH

Preview of ASH Highlights [OBR]

5.8.1 ASH - Communiqués

Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients at the 2017 American Society of Hematology Annual Meeting (ASH) [Astellas]

6. Lutte contre les cancers

Tenovus to build 'world's biggest' mobile chemotherapy unit [BBC News]

6.1 Observation

Men twice as likely to develop oral cancer [Cancer Research UK]

6.6 Publications

PLOS Reports $1.7M Loss In 2016 [The Scholarly Kitchen]

6.7.1 Bioinformatique

Some roadblocks to the broad adoption of machine learning and AI [Simply Statistics]

6.9 Controverses

Five ways to fix statistics [Nature]